A protein may help brain tumors hide from the immune system
Original title: IFI30 reprograms glioblastoma-associated macrophage and induces immune evasion by MAFF/PTGS2 pathway.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in the lab and in animals, not in people.
The short version
Scientists found a protein that seems to help brain tumors block the body's defenses.
What was studied. Researchers looked at a protein called IFI30 in glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary, a fast growing brain tumor. They used computer data, tumor cells in the lab, and tests in animals.
What they found. IFI30 levels were high in glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary. The protein changed which immune cells moved into the tumor. It also lowered the share of CD8+ T cells, a kind of immune cell that helps fight tumors. The team mapped the steps the protein used to do this.
What this means, and what it doesn't
What it could mean: IFI30 could become a target for future treatments. Blocking it might help the immune system fight the tumor. That idea still has to be tested.
What it doesn't mean: This does not mean there is a new treatment. The work was done in lab dishes, in computer data, and in animals. It was not tested in people. It is not a cure, and it is far from everyday care. Much more testing would come first, and many findings like this never become a drug.
Source: PubMed, June 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.